Afasci, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.afasci.com
A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- AlcoholAlcohol Use Disorders
- Interventions
- Drug: AFA-281 is a small molecule, orally availableOther: Alcohol (Ethanol)
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Afasci Inc
- Target Recruit Count
- 20
- Registration Number
- NCT06719908
A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder
Phase 2
Not yet recruiting
- Conditions
- Alcohol AbuseAlcohol Abuse/addictionAnxietyPain ThresholdDepression DisordersSleep Disorder
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Afasci Inc
- Target Recruit Count
- 36
- Registration Number
- NCT06710431
- Locations
- 🇺🇸
University of California, Los Angeles, California, United States
Efficacy Study With AFA-281 for the Treatment of Back Pain
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Afasci Inc
- Target Recruit Count
- 372
- Registration Number
- NCT06649747
Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Afasci Inc
- Target Recruit Count
- 58
- Registration Number
- NCT05547503
- Locations
- 🇺🇸
CenExcel CNS, Los Alamitos, California, United States
© Copyright 2025. All Rights Reserved by MedPath